Abstract:Equine herpesvirus type 1 (EHV-1) is one of the most prevalent respiratory pathogens in horses with a high impact on animal health worldwide. Entry of the virus into epithelial cells of the upper respiratory tract and rapid local viral replication is followed by infection of local lymphoid tissues leading to cell-associated viremia and disease progression. Pre-existing mucosal immunity has previously been shown to reduce viral shedding and prevent viremia, consequently limiting severe disease manifestations. Here, nasopharyngeal transcriptomic profiling was used to identify differentially expressed genes following EHV-1 challenge in horses with different EHV-1 immune statuses. Immune horses (n = 4) did neither develop clinical disease nor viremia and did not shed virus after experimental infection, while non-immune horses (n = 4) did all the above. RNA sequencing was performed on nasopharyngeal samples pre- and 24 hours post-infection (24hpi). At 24hpi, 109 and 44 genes were upregulated in immune horses and non-immune horses, respectively, and three genes were explored in further detail. Antileukoproteinase (SLPI) gene expression increased 2.1-fold within 24 hours in immune horses in concert with protein secretion. Interferon (IFN)-induced proteins with tetratricopeptide repeats 2 (IFIT2) and 3 (IFIT3) were upregulated in non-immune horses, corresponding with nasal IFN-α secretion and viral replication. By contrast, neither IFIT expression nor IFN-α secretion was induced by EHV-1 infection of immune horses. Transcriptomic profiling offered a tool to identify, for the first time, the role of SLPI in innate immunity against EHV-1, and further emphasized the central role of the type I IFN response in the anti-viral defense of non-immune horses. Importance: Equine herpesvirus type 1 (EHV-1) remains a considerable concern in the equine industry, with yearly outbreaks resulting in morbidity, mortality, and economic losses. In addition to its importance in equine health, EHV-1 is a respiratory pathogen and an alphaherpesvirus, and it may serve as a model for other viruses with similar pathogenicity or phylogeny. Large animal models allow the collection of high-volume samples longitudinally, permitting in-depth investigation of immunological processes. This study was performed on bio-banked nasopharyngeal samples from an EHV-1 infection experiment, where clinical outcomes had previously been determined. Matched nucleic acid and protein samples throughout infection permitted longitudinal quantification of the protein or related proteins of selected differentially expressed genes detected during the transcriptomic screen. The results of this manuscript identified novel innate immune pathways of the upper respiratory tract during the first 24 hours of EHV-1 infection, offering a first look at the components of early mucosal immunity that are indicative of protection.

[Elevation of IFN-gamma Transcription Level in Peripheral Blood Mononuclear Cells of EIAV Vaccinated Horses].

Elevation of IL-2 Expressing Level in PBMC of EIAV Vaccinated Horses

[Induction of EIAV-specific Cellular Immune Response by Attenuated EIAV Vaccine].

A Pilot Study on an Attenuated Chinese EIAV Vaccine Inducing Broadly Neutralizing Antibodies

[A Flow Cytometric Assay for the Expression of Interferon Gamma in T Lymphocytes and Its Application in the Study of EIAV-induced Immune Response].

An Attenuated EIAV Vaccine Strain Induces Significantly Different Immune Responses from Its Pathogenic Parental Strain Although with Similar in Vivo Replication Pattern

A Pilot Study Comparing the Development of EIAV Env-Specific Antibodies Induced by DNA/Recombinant Vaccinia-Vectored Vaccines and an Attenuated Chinese EIAV Vaccine

[Expression and Immunogenicity of Equine Infectious Anemia Virus Membrane Protein GP90].

Quantification of Equine Infectious Anemia Virus RNA in Horse Plasma by a Real-Time PCR Assay

Transient Immune Suppression of Inapparent Carrier Ponies Inoculated with Attenuated Equine Infectious Anemia Virus Infectious Clone.

Study on the Infectivity of Vaccinia Virus in Equine Cells

In vivo evolution of the gp90 gene and consistently low plasma viral load during transient immune suppression demonstrate the safety of an attenuated equine infectious anemia virus (EIAV) vaccine

Combined amino acid mutations occurring in the envelope closely correlate with pathogenicity of EIAV

A Pilot Study on Interaction Between Donkey Tetherin and EIAV Stains with Different Virulent and Replication Characteristics.

Long Terminal Repeat Sequences from Virulent and Attenuated Equine Infectious Anemia Virus Demonstrate Distinct Promoter Activities.

Proteomic alteration of equine monocyte-derived macrophages infected with equine infectious anemia virus.

In Vivo Evolution of Gag and Gp45 Genes of Equine Infectious Anemia Virus

Immune horses rapidly increase antileukoproteinase and lack type I interferon secretion during mucosal innate immune responses against equine herpesvirus type 1

Immunogenicity of Calvenza-03 EIV/EHV® Vaccine in Horses: Comparative In Vivo Study

Monitoring of effects induced by recombinant equine interferon-beta 1 in whole blood and separated fractions of peripheral blood of horses

Genetic Evolution of Equine Infectious Anemia Virus LTR Region During Attenuation in Vitro.